Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Blood Test Pinpoints Cause of Brain Injury in Newborns

By LabMedica International staff writers
Posted on 05 Feb 2024

Hypoxic-Ischemic Encephalopathy (HIE), also known as birth asphyxia, is a brain injury that occurs when a newborn's brain does not receive sufficient oxygen either before or just after birth. This condition is a major cause of death and disability in full-term babies worldwide, impacting about three million infants annually. Brain damage from oxygen deprivation can develop over a period ranging from hours to months, potentially impacting various brain areas and leading to diverse neurodisabilities such as cerebral palsy, epilepsy, and sensory impairments like deafness or blindness. South Asia, especially India, bears the brunt of this issue, with 60% of global HIE-related fatalities occurring in the country. Now, a blood test can pinpoint the underlying cause of brain injury in newborns and assist in making informed treatment choices.

In a study of infants with HIE, researchers from Imperial College London (London, UK) discovered that blood-based gene expression patterns can indicate the injury's origin and predict the infant's likelihood of responding to cooling treatment, a common method for treating brain injuries in babies. This advancement could pave the way for a simple blood test that rapidly diagnoses brain injuries in newborns, aiding in treatment decisions. The research included babies from both low and middle-income countries (LMICs) and high-income countries (HICs), revealing a stark contrast in gene expression between these groups, suggesting differing causes of brain injury.

Previous research, primarily in HICs, has shown that whole-body cooling can enhance recovery prospects for babies with HIE. This has led to its widespread adoption as standard practice in many HICs and some hospitals in South Asia. However, the most extensive study of its kind in LMICs, conducted by Imperial College London and its partners in India, Bangladesh, and Sri Lanka, had previously found that whole-body cooling might actually worsen outcomes and increase mortality risks in babies with HIE in these regions. The new study sheds light on why babies from different regions respond differently to cooling treatment and holds the potential for the development of a simple blood test to identify which infants will benefit from it. The research, a collaboration between Imperial College London and its South Asian partners, involved 35 Italian (a HIC) and 99 South Asian (from LMICs) newborns with HIE. Blood samples were collected soon after birth, and the infants were evaluated medically at 18 months.

About half of the babies in the South Asian group either passed away or developed severe disabilities, compared to a quarter in the Italian group. The researchers analyzed the correlation between gene expression at birth and outcomes at 18 months in both groups. They identified 1793 significant genes linked to adverse outcomes in the HIC group and 99 in the South Asian group, with only 11 significant genes common to both groups, but expressed differently. The researchers emphasized that these differences are not due to ethnic factors but rather socioeconomic ones. The type of chronic brain injury common in LMICs can also be found in impoverished areas of HICs. Conversely, in wealthier regions of LMICs, one might find more cases of acute brain injury, similar to those typically seen in HICs in this study.

“The key for clinicians, anywhere in the world, is to be able to identify which type of brain injury they are dealing with as soon as possible – and that’s something we’re currently working on,” said lead investigator, Professor Sudhin Thayyil from the Department of Brain Sciences at Imperial College London.

Related Links:
Imperial College London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.